Shares of INVO Bioscience, Inc. (NASDAQ:INVO – Get Free Report) fell 0.2% during trading on Thursday . The stock traded as low as $0.45 and last traded at $0.46. 21,488 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,587,563 shares. The stock had previously closed at $0.46.
INVO Bioscience Trading Down 5.4 %
The company’s fifty day moving average is $0.70 and its 200-day moving average is $0.78.
Institutional Investors Weigh In On INVO Bioscience
An institutional investor recently bought a new position in INVO Bioscience stock. CWC Advisors LLC. bought a new position in shares of INVO Bioscience, Inc. (NASDAQ:INVO – Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 100,477 shares of the company’s stock, valued at approximately $71,000. CWC Advisors LLC. owned 2.64% of INVO Bioscience at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.02% of the company’s stock.
About INVO Bioscience
INVO Bioscience, Inc, together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.
Recommended Stories
- Five stocks we like better than INVO Bioscience
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
- Which Wall Street Analysts are the Most Accurate?
- Why New Tariffs Could Boost These 3 Basic Materials Stocks
- What Are Dividend Achievers? An Introduction
- MarketBeat Week in Review – 02/03 – 02/07
Receive News & Ratings for INVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.